38 Results

People

  1. Goldberg
    Goldberg
  2. Stein
    Stein
  3. Klimek
    Klimek
  4. Rampal
    Rampal
  5. Stahl
    Stahl
  6. Tallman
    Tallman
  7. Derkach
    Derkach
  8. Levine
    Levine
  9. Roshal
    Roshal
  10. Xiao
    Xiao

Groups

  1. Center for Hematologic Malignancies (27)
  2. Department of Medicine (27)
  3. Hematologic Malignancies, Division of (27)
  4. Adult Leukemia (23)
  5. Hematology-Oncology Fellows (9)
  6. Weinberg Fellows (8)
  7. Department of Pathology and Laboratory Medicine (6)
  8. GSK Faculty (6)
  9. Graduate Medical Education (6)
  10. Epidemiology and Biostatistics (5)
  1. "decitabine"
Formats
  1. Journal Article (26)
  2. Review (11)
  3. Research Letter (1)
Groups
  1. Center for Hematologic Malignancies (27)
  2. Department of Medicine (27)
  3. Hematologic Malignancies, Division of (27)
  4. Adult Leukemia (23)
  5. Hematology-Oncology Fellows (9)
  6. Weinberg Fellows (8)

More Groups

People
  1. Eytan Stein (9)
  2. Aaron Goldberg (6)
  3. Martin Tallman (6)
  4. Virginia Klimek (5)
  5. Maximilian Stahl (4)
  6. Raajit Rampal (4)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (9)
  4. 2022 (2)
  5. 2021 (3)
  6. 2020 (5)

More Years

Publications
  1. Blood Advances (6)
  2. Leukemia and Lymphoma (4)
  3. Blood Reviews (3)
  4. Cancer (3)
  5. Expert Review of Hematology (2)
  6. Leukemia (2)

More Publications

Publishers
  1. American Society of Hematology (7)
  2. Taylor & Francis Group (6)
  3. Churchill Livingstone (3)
  4. Nature Publishing Group (3)
  5. Springer (3)
  6. Wiley Blackwell (3)

More Publishers

Results (38)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
    Journal Article

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G. K.; Borge, P. D.; Geyer, M.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L. E.; more...
    Leukemia and Lymphoma (2025)

    Fulltext@MSK | Save
  • Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: Updated recommendations by the EBMT/ELN International Working Group
    Review

    Kröger, N.; Bacigalupo, A.; Barbui, T.; Ditschkowski, M.; Gagelmann, N.; Griesshammer, M.; Gupta, V.; Hamad, N.; Harrison, C.; Hernandez-Boluda, J. C.; more...
    The Lancet Haematology (2024)

    Fulltext@MSK | Save
  • Targeting apoptosis dysregulation in myeloid malignancies - The promise of a therapeutic revolution
    Review

    Santinelli, E.; Pascale, M. R.; Xie, Z.; Badar, T.; Stahl, M. F.; Bewersdorf, J. P.; Gurnari, C.; Zeidan, A. M.
    Blood Reviews (2023)

    Fulltext@MSK | Save
  • IDH1/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: A multicentre experience
    Research Letter

    Gangat, N.; Ajufo, H.; Abdelmagid, M.; Karrar, O.; McCullough, K.; Badar, T.; Foran, J.; Palmer, J.; Alkhateeb, H.; Mangaonkar, A.; more...
    British Journal of Haematology (2023)

    Fulltext@MSK | Save
  • Clinical status of induction therapy incorporating a hypomethylating agent for newly diagnosed adult acute myeloid leukemia compared to the standard 7+3 regimen
    Review

    Ohmoto, A.; Fuji, S.
    Expert Review of Hematology (2023)

    Fulltext@MSK | Save
  • Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms
    Journal Article

    Nannya, Y.; Tobiasson, M.; Sato, S.; Bernard, E.; Ohtake, S.; Takeda, J.; Creignou, M.; Zhao, L.; Kusakabe, M.; Shibata, Y.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
    Journal Article

    Duong, V. H.; Ruppert, A. S.; Mims, A. S.; Borate, U.; Stein, E. M.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Arellano, M. L.; more...
    Cancer (2023)

    Fulltext@MSK | Save
  • Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
    Journal Article

    de Botton, S.; Cluzeau, T.; Vigil, C.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Liesveld, J. L.; Fenaux, P.; Braun, T.; Banos, A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • What’s next after hypomethylating agents failure in myeloid neoplasms? A rational approach
    Review

    Awada, H.; Gurnari, C.; Xie, Z.; Bewersdorf, J. P.; Zeidan, A. M.
    Cancers (2023)

    Fulltext@MSK | Save
  • Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors
    Journal Article

    Bewersdorf, J. P.; Shallis, R. M.; Derkach, A.; Goldberg, A. D.; Stein, A.; Stein, E. M.; Marcucci, G.; Zeidan, A. M.; Shimony, S.; DeAngelo, D. J.; more...
    Leukemia and Lymphoma (2023)

    Fulltext@MSK | Save